MEG3 can act as an agonist of cisplatin in suppressing triple-negative breast cancer (TNBC) growth and metastasis potentials, and facilitate pyroptosis by activating cisplatin-induced NLRP3/caspase-1/gasdermin D (GSDMD) pathway [134]. The gene discussed is GSDMD; the disease is triple-negative breast carcinoma.